XORTX Therapeutics Inc. develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease.The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19.
